Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature.
Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature.
复制标题
DOI：
10.3390/jcm11195759
复制
发表时间：
2022-09-28
影响因子：
3.9
通讯作者：
Parodis I
中科院分区：
文献类型：
--
作者：
Palazzo L;Lindblom J;Mohan C;Parodis I
狼疮性肾炎(LN)是系统性红斑狼疮(SLE)患者发病和死亡的主要原因。然而，前景看好的新兴生物标志物为改善LN患者的管理铺平了道路。我们回顾了过去十年的文献，在此我们总结了与LN的诊断、监测和预后最相关的生物标志物。对Medline进行了初步的系统搜索，以确定相关文章。共有104项研究被选入本综述。一些诊断生物标志物，包括MCP-1、TWEE、NGAL和尿酸，显示出很好的区分LN患者和非肾性SLE患者的能力。几种细胞因子和趋化因子，包括IL-10、IL-17、MCP-1和IP-10，以及细胞黏附分子(CAM)都有望用于评估LN的疾病活动性。与血管生成和止血相关的蛋白也显示出监测疾病活动的潜力。治疗反应的生物标记物包括AXL、CD163和BAFF，而VCAM-1、ALCAM和ANCA已被报道为预后标记物，与传统标记物一样。此外，新的肾组织生物标记物可能被证明是组织学评估的有用补充。不同研究的纳入标准和结果衡量标准的总体异质性，以及多中心队列中缺乏验证，需要未来的合作努力。然而，我们预计有几个生物标记物有望优化LN的管理，使用集成的组学和侵入性较小的生物标记物小组为个性化药物铺平道路。
Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). However, promising emerging biomarkers pave the way toward an improved management of patients with LN. We have reviewed the literature over the past decade, and we herein summarise the most relevant biomarkers for diagnosis, monitoring, and prognosis in LN. An initial systematic search of Medline was conducted to identify pertinent articles. A total of 104 studies were selected to be included in this review. Several diagnostic biomarkers, including MCP-1, TWEAK, NGAL, and uric acid, exhibited good ability to differentiate LN patients from non-renal SLE patients. Several cytokines and chemokines, including IL-10, IL-17, MCP-1, and IP-10, hold promise for assessing LN disease activity, as do cell adhesion molecules (CAMs). Angiogenesis-related and haemostasis-related proteins have also displayed potential for monitoring disease activity. Biomarkers of responses to therapy include Axl, CD163, and BAFF, whereas VCAM-1, ALCAM, and ANCAs have been reported as prognostic markers, along with traditional markers. In addition, novel renal tissue biomarkers may prove to be a useful complement to histological evaluations. The overall heterogeneity of the inclusion criteria and outcome measures across different studies, along with a lack of validation in multi-centre cohorts, call for future collaborative efforts. Nevertheless, we foresee that several biomarkers hold promise toward optimisation of the management of LN, with the use of integrated omics and panels of less invasive biomarkers paving the way towards personalised medicine.
登录
查看更多内容
影响因子：
11.2
作者：
Chakraborty, Subhankar;Kaur, Sukhwinder;Guha, Sushovan;Batra, Surinder K.
通讯作者：
Batra, Surinder K.
影响因子：
13.6
作者：
Bruschi, Maurizio;Sinico, Renato Alberto;Ghiggeri, Gian Marco
通讯作者：
Ghiggeri, Gian Marco
影响因子：
5.1
作者：
Bagavant H;Fu SM
通讯作者：
Fu SM
影响因子：
4
作者：
Alharazy S;Kong NC;Mohd M;Shah SA;Ba'in A;Abdul Gafor AH
通讯作者：
Abdul Gafor AH
DOI：
10.1172/jci147334
发表时间：
2022-01-04
期刊：
The Journal of clinical investigation
影响因子：
--
作者：
Chalmers SA;Ayilam Ramachandran R;Garcia SJ;Der E;Herlitz L;Ampudia J;Chu D;Jordan N;Zhang T;Parodis I;Gunnarsson I;Ding H;Shen N;Petri M;Mok CC;Saxena R;Polu KR;Connelly S;Ng CT;Mohan C;Putterman C
通讯作者：
Putterman C